comprising the amino acid sequence of SEQ ID NO:68, a CDRH2 comprising the amino acid sequence of SEQ ID NO:69, a CDRH3 comprising the amino acid sequence of SEQ ID NO:70, a CDRL1 comprising the amino acid sequence of SEQ ID NO:98, a CDRH2 comprising the amino acid sequence of SEQ ID NO:99, a CDRH3 comprising the amino acid sequence of SEQ ID NO:100.

15. The method of claim **9**, wherein the subject is of age 60 or older, is immunocompromised, or suffers from a respiratory and/or cardiovascular disorder.

16. The method of claim **9**, wherein the delivering is prior to infection.

17. The method of claim **9**, wherein the delivering is after infection.

18. A vaccine formulation comprising one or more antibodies or antibody fragments of claim **1**.

19. The vaccine formulation of claim **18**, further comprising a second antibody or antibody fragment that binds to a SARS-CoV-2 surface spike protein.

20. A vaccine formulation comprising one or more expression vectors encoding a first antibody or antibody fragment according to claim **1**.

21. A method of detecting COVID-19 infection with SARS-CoV-2 in a subject comprising

(a) contacting a sample from the subject with the antibody or fragment of claim **1**; and

(b) detecting SARS-CoV-2 in the sample by binding of the antibody or antibody fragment to a SARS-CoV-2 antigen in the sample.

22. A method of determining the antigenic integrity, correct conformation and/or correct sequence of a SARS-CoV-2 surface spike protein comprising:

(a) contacting a sample comprising the antigen with the antibody or fragment of claim **1**; and

(b) determining antigenic integrity, correct conformation and/or correct sequence of the antigen by detectable binding of the antibody or antibody fragment to the antigen.

23. A hybridoma or engineered cell comprising a polynucleotide encoding the antibody or antibody fragment of claim **1**.

24. An isolated human monoclonal antibody or antibody fragment, or hybridoma or engineered cell producing the same, wherein the antibody binds to a SARS-CoV-2 surface spike protein.

25. An isolated polynucleotide comprising a nucleic acid sequence encoding the heavy chain variable region of the antibody or antibody fragment of claim **1** and/or a nucleic acid sequence encoding the light chain variable region of the antibody or antibody fragment.

26. A vector comprising the polynucleotide of claim **25**.

27. A host cell comprising the vector of claim **26**.

28. A method of making an antibody or antibody fragment comprising (a) culturing the cell of claim **27**; and (b) isolating the antibody or antibody fragment thereof from the cultured cell.

29. A composition or kit comprising a first antibody or antibody fragment that binds to a SARS-CoV-2 surface spike protein and a second antibody or antibody fragment that binds to a SAR-CoV-2 surface spike protein, optionally wherein the composition is a pharmaceutically acceptable composition.

30. The kit of claim **29**, wherein the first antibody or antibody fragment and the second antibody or antibody fragment are in separate containers.

* * * * *